scholarly journals Clinically Amyopathic Dermatomyositis Associated with Recurrence of Esophageal Cancer: A Case Report

2021 ◽  
Vol 5 (3) ◽  
pp. 297-300
Author(s):  
Anna Eversman ◽  
Sayeeda Ahsanuddin ◽  
Joel Saltzman ◽  
Paula Silverman ◽  
Mara Beveridge
Keyword(s):  
Esophageal Cancer ◽  
Case Report ◽  
Esophageal Adenocarcinoma ◽  
Clinical Significance ◽  
Amyopathic Dermatomyositis ◽  
Case Presentation ◽  
Skin Changes ◽  
Clinically Amyopathic Dermatomyositis ◽  
Clinical Interest ◽  
New Onset

Background: Approximately 20% of patients displaying skin changes characteristic of dermatomyositis do not develop clinical or enzymatic evidence of muscle inflammation within 6 months of onset, leading to a diagnosis of clinically amyopathic dermatomyositis (CADM). While the association between dermatomyositis and malignancy is well-documented, the clinical significance of CADM is still being elucidated. Case Presentation: We report a case of new-onset CADM associated with recurrent esophageal adenocarcinoma for clinical interest and to add to the limited literature on CADM. Conclusion: To date, there is only one report of concurrent CADM and esophageal cancer. We present this case for clinical interest and to add to the limited literature on CADM.

scholarly journals Case report: a 5-year-old with new onset nephrotic syndrome in the setting of COVID-19 infection

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Kelsi M. Morgan ◽  
Peace D. Imani
Keyword(s):  
Nephrotic Syndrome ◽  
Case Report ◽  
Pediatric Patient ◽  
Corticosteroid Therapy ◽  
Clinical Remission ◽  
Laboratory Findings ◽  
Case Presentation ◽  
The Third ◽  
First Case ◽  
New Onset

Abstract Background This is a case report of an asymptomatic SARS-CoV-2 infection associated with new-onset nephrotic syndrome in a pediatric patient. This is the third case of new-onset nephrotic syndrome in children associated with SARS-CoV-2 infection, but is the first case report describing a new-onset nephrotic syndrome presentation in a patient who had asymptomatic COVID-19 infection. Case presentation This is a case of a previously healthy 5 year old female who presented with new-onset nephrotic syndrome in the setting of an asymptomatic COVID-19 infection. She presented with progressive edema, and laboratory findings were significant for proteinuria and hypercholesterolemia. She was treated with albumin, diuretics, and corticosteroid therapy, and achieved clinical remission of her nephrotic syndrome within 3 weeks of treatment. Though she was at risk of hypercoagulability due to her COVID-19 infection and nephrotic syndrome, she was not treated with anticoagulation, and did not develop any thrombotic events. Conclusions Our case report indicates that SARS-CoV-2 infection could be a trigger for nephrotic syndrome, even in the absence of overt COVID-19 symptoms.

scholarly journals New Onset Focal Seizure Following COVID-19 Vaccination: Case Report

2021 ◽  
Author(s):  
Chun Seng Phua ◽  
Shalini Bhaskar ◽  
Azman Ali Raymond
Keyword(s):  
Case Report ◽  
Side Effects ◽  
Focal Seizure ◽  
Seizure Threshold ◽  
Hippocampal Atrophy ◽  
Case Presentation ◽  
Mri Brain ◽  
Focal Seizures ◽  
Patient’S History ◽  
New Onset

Abstract IntroductionAs more novel COVID-19 vaccines are being rolled out in a frantic pace globally, any complication that might be related to COVID-19 vaccines should be highlighted, especially since COVID-19 vaccines are relatively new, and side effects may yet to be fully elucidated. We report a case of a healthy 18-year-old male who presented with new onset focal seizures 5 days after receiving 1st dose of Oxford/AstraZeneca COVID-19 vaccine. Case PresentationThe patient was treated with intravenous phenytoin and oral levetiracetam 250mg twice daily with no further events. There was no documented fever. CT venogram and EEG were unremarkable. MRI brain revealed generalised atrophy including mild bilateral hippocampal atrophy with no evidence of sclerosis. There was no predilection for seizures identified from the patient’s history. The patient was discharged the following day on levetiracetam and advised to proceed with the 2nd dose of Oxford/AstraZeneca COVID-19 vaccination in 3 months’ time.ConclusionSeizures following COVID-19 vaccination have only been reported in a handful of cases. COVID-19 vaccination could lower seizure threshold, or unmask an underlying predisposition for epilepsy. As most COVID-19 vaccines worldwide are given in 2 doses, clinicians should consider maintaining patients on anti-seizure drugs if vaccination was thought to be a provoking factor.

scholarly journals Anti-EJ, anti-MDA5 double-positive chronic clinically amyopathic dermatomyositis: a case report

2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Yusuke Takeuchi ◽  
Motomu Hashimoto ◽  
Ran Nakashima ◽  
Masao Tanaka ◽  
Nobuo Kuramoto ◽  
...  
Keyword(s):  
Case Report ◽  
Amyopathic Dermatomyositis ◽  
Double Positive ◽  
Clinically Amyopathic Dermatomyositis

scholarly journals Pravastatin-Induced Eczematous Eruption Mimicking Psoriasis

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Michael P. Salna ◽  
Hannah M. Singer ◽  
Ali N. Dana
Keyword(s):  
Case Report ◽  
Clinical Presentation ◽  
The Elderly ◽  
Case Presentation ◽  
Dermatology Clinic ◽  
Systemic Treatments ◽  
Eczematous Dermatitis ◽  
Erythematous Plaques ◽  
New Onset

Background. Statins, an example of the most commonly prescribed medications to the elderly, are not without side effects. Dermatologic events are often overlooked as arising from medications, particularly those which are taken chronically. Moreover, elderly patients are prone to pharmacologic interactions due to multiple medications. In this report, we describe a case of a statin-induced eczematous dermatitis with a psoriasis-like clinical presentation and review the skin manifestations that may arise from statin therapy.Case Presentation. An 82-year-old man with gout and hypercholesterolemia presented to dermatology clinic with new onset of pruritic, scaly erythematous plaques bilaterally on the extensor surfaces of his arms. He had never had similar lesions before. Despite various topical and systemic treatments over several months, the rash continued to evolve. The patient was then advised to discontinue his long-term statin, which led to gradual resolution of his symptoms. He was subsequently diagnosed with statin-induced eczematous dermatitis.Conclusions. This case report describes an adverse cutaneous reaction to statins that is rarely reported in the literature. Medications, including longstanding therapies, should be suspected in cases of refractory dermatologic lesions.

scholarly journals Clinically Amyopathic Dermatomyositis Caused by a Tattoo

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Bing Han ◽  
Qiang Guo
Keyword(s):  
Immune Response ◽  
Case Report ◽  
Interstitial Lung Disease ◽  
Laboratory Test ◽  
Clinical Presentation ◽  
Unknown Origin ◽  
Skin Lesions ◽  
Amyopathic Dermatomyositis ◽  
Clinically Amyopathic Dermatomyositis ◽  
Left Chest

Introduction. Clinically amyopathic dermatomyositis (CADM) is a rare disease with unknown origin. It is characterized by the specific skin lesions of dermatomyositis (DM) without clinical or laboratory evidence of myopathy. Previous studies indicated that tattoo may induce immune response. Case Report. A 22-year-old male who tattooed butterfly on the left chest with blue and red ink. Then, he gradually had typical Gottron rash and interstitial lung disease (ILD) without weakness of the muscle. The clinical presentation and laboratory test represent the diagnosis of CADM. According to the history, CADM was induced by the tattoo five months before admission. Discussion. We first reported the CADM induced by a tattoo. However, further studies are still needed to approach the specific substances within the tattoo that trigger immune response.

Sign in / Sign up

Export Citation Format

Share Document